Unpacking Wave’s PRECISION-HD2 huntingtin-lowering trial announcement
Just before the new year, Wave announced that the drug in the PRECISION-HD2 trial had successfully lowered the concentration of mutant huntingtin in the spinal fluid. By Dr Jeff Carroll | Edited by Dr Ed WildPublished January 03, 2020 at www.HDBuzz.net DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production […]